Scolr Pharma, Inc.
SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
Published in Medical Letter on the CDC and FDA, November 23rd, 2008
Daniel O. Wilds, SCOLR Pharma's President and CEO, said, "We had a very productive third quarter making significant progress advancing our lead product candidates and securing additional non-dilutive operating capital while maintaining financial discipline. Most importantly, yesterday we reported favorable top-line results from our pivotal Phase III trial to evaluate the safety and efficacy of our 12 hour CDT(R) 600 mg extended-release (ER) ibuprofen...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Adverse Drug Reactions
Dermipsor Reports Positive Phase 2b Results Showing Efficacy and Synergy of its Leading Product DPS-101, a Non- Steroidal Combination Drug to Treat Psoriasis the data showed statistical significant efficacy in most arms. - Alexza Pharmaceuticals, Inc.
Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates - Angiogenesis
Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models - Cancer
Data Presented At Cancer Molecular Markers Meeting Suggests Clinical Benefit for Integrating New Molecular Tests - Fibromyalgia
Research data from M. Spaeth and colleagues update understanding of fibromyalgia - Fibromyalgia
Studies from Arizona State University add new findings in the area of fibromyalgia - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
